Search

Search Constraints

You searched for: Author/Creator Yong, Wei Peng

Search Results

1. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Issue 5 (7th February 2012)

2. An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma. (31st December 2018)

3. Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. (2nd December 2022)

4. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Issue 5 (7th October 2020)

5. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Issue 7 (25th August 2021)

6. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. (10th October 2021)

7. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. (October 2021)

8. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Issue 1 (25th April 2012)

9. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. (November 2021)

10. Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients. (1st June 2018)